Molecular Medicine Tumor Board: Whole-Genome Sequencing to Inform on Personalized Medicine for a Man with Advanced Prostate Cancer – Beyond the Abstract

This molecular tumor board is a rare example of having complete whole-genome sequencing data from the germline and tumor in a living patient facing aggressive prostate cancer in real-time. We provide a case report of how our multidisciplinary team of medical oncologists, pathologists, cancer biologists, and bioinformatics specialists thinks through the complexities of this big […]

Partnering up with Abiraterone Acetate – Potentials for a Harmonious Relationship

Abiraterone acetate has demonstrated benefit across the metastatic prostate cancer spectrum when combined or layered on conventional androgen deprivation therapy. Whether it be metastatic castration-sensitive (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC) in either the pre-or the post-docetaxel setting, the overall survival benefit is certain.1-4 Attempts to advance to the next level with additional agents […]

Global Assessments of the Endockscope System: Long-Term Impact of Cyber Endoscopy.

The disproportionate costs of state-of-the-art endoscopic equipment prohibit urologists from performing endoscopy in underserved countries. Given the global prevalence of smartphones, we engineered a $45 alternative endoscope utilizing three-dimensional (3D) printed attachments, an 8x lens, and a 1,000-lumen light-emitting diode (LED) cordless flashlight (Endockscope System (ES)).

Comparing two different low-intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two-arm, parallel-group randomized controlled trial.

Despite encouraging results, the optimal low-intensity shockwave therapy (LiST) protocol in patients with chronic prostatitis/chronic pelvic pain syndrome (CPPS) remains unknown. We conducted a two-arm, parallel-group, randomized controlled trial aiming to compare the efficacy and safety of six LiST sessions applied once or twice weekly.

X